Primary giant hepatic neuroendocrine carcinoma: A case report  by Rocca, Aldo et al.
lable at ScienceDirect
International Journal of Surgery 12 (2014) S218eS221Contents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netPrimary giant hepatic neuroendocrine carcinoma: A case report
Aldo Rocca a, *, Fulvio Calise b, Giuseppina Marino c, Stefania Montagnani d,
Mariapia Cinelli d, Bruno Amato a, Germano Guerra e
a Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy
b Hepatobiliary Surgery and Liver Transplant Center, A. Cardarelli Hospital, Naples, Italy
c Pathology Unit, A. Cardarelli Hospital, Naples, Italy
d Department of Public Health, University of Naples “Federico II”, Naples, Italy
e Department of Medicine and Health Sciences, University of Molise, Campobasso, Italya r t i c l e i n f o
Article history:
Received 23 March 2014
Accepted 3 May 2014






Transarterial embolization* Corresponding author. Department of Clinical Med
of Naples “Federico II”, Via Sergio Pansini, 80131 Nap
E-mail address: aldorocca@hotmail.it (A. Rocca).
http://dx.doi.org/10.1016/j.ijsu.2014.05.056
1743-9191/© 2014 Surgical Associates Ltd. Publisheda b s t r a c t
Carcinoid tumours arise from neuroendocrine cells and may develop in almost any organ. These type of
tumours actually are correctly termed neuroendocrine tumours. Hepatic neuroendocrine carcinomas
rarely arise as primary tumour; in fact on 100 cases reported in literature just a few of these are of
primary nature. We report the case of a giant hepatic neuroendocrine carcinoma in a 55-year-old man.
The symptoms were only recurrent hypoglycemia and an abdominal mass. Diagnosis was performed by
blood analysis, ultrasonography, TC scan and In111-DTPA-octreotide scan. Surgical treatment occurred by
an en bloc removal of the mass and a wide resection with free margins. Histological examination
conﬁrmed diagnosis. Clinical and instrumental diagnostic follow-up show the patient still alive, in very
good conditions and disease free two years after surgery.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Primary hepatic carcinoids actually termed neuroendocrine
carcinomas are rare tumours that are often diagnosed at a locally
advanced stage. Despite about 100 reports in the literature very
little information are known of primary hepatic carcinoids [1e8].
Several different investigations and long-term follow-up are
necessary to ascertain the primary nature of these lesions. The
majority is discovered accidentally when the tumour is already big
and developed. They often present a large size and central liver
localization but despite these discouraging resection approaches
aggressive surgical treatment remains the gold standard therapy.
Tumours not amenable to liver resection should be treated by
chemotherapy or liver transplantation. Surgical treatment outcome
data are not clear but long-term survival of most patients justify an
aggressive surgical approach. We present a case of a 55 years old
manwho had a 30 cm tumour of the left liver, who is still alive and
disease free two years after surgery.icine and Surgery, University
les, Italy.
by Elsevier Ltd. All rights reserved2. Case report
A 55-year-old man in good state of health complained of
recurrent hypoglycemia. There was no history of liver failure,
haematemesis, ﬂushing, or diarrhoea. Hypoglycemic status induced
patient to come at our emergency room. Clinical examination
showed a palpable hepatomegaly and large mass in epigastrium
and left hypochondrium. Abdominal ultrasound scan revealed a
heterogeneous 30 cm left lobe focal liver lesion. Contrast enhanced
CT performed three days later showed a solid 183  158  214 cm
little wing liver mass with a soft enhancement, an hypodense core
with large colliquative areas and minute central calciﬁcations.
Laboratory data showed normal blood tests except for low levels of
serum albumin 2.8 g/dl, and potassium 2.4 mEq/l. Hepatitis B and C
serologies were negative. Serum tumour markers including CEA,
AFP, CA 12.5, CA 19.9, gastrin and NSEwere in the range level, while
Chromogranin A were 3972 U/L with a range value 2.0e18.0. Chest
CT didn't show any pathological sign or marker of metastasis linked
to lung or linfonodes. We performed also an oesopha-
guseduodenumegastroscopy which showed widespread and se-
vere gastropathy interested gastric fundus and body. Compression
ab exstriseco of the bulb and of duodenum. Liver biopsy conﬁrmed
suspect of NET (neuroendocrine tumour), it was positive for syn-
aptophysin, CD 56, Ki67 proliferation index of 10% with diagnosis of.
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perform also In111-DTPA-octreotide scan, which conﬁrm a hyper
intense accumulation of the marker at the known massive hepatic
neoplasm. No other site of accumulation were found. During lap-
arotomy we found a mass of 30 cm interesting IIs, IIIs, IVs, and
which arrives since umbilical line thorough exploration of the
abdominal cavity, small bowel, and mesentery was performed. We
performed also intraoperative ultrasound scan which showed that
the mass compresses the middle hepatic vein, while the right he-
patic vein is pervious, but moved posteriorly. Ultrasounds
conﬁrmed that right lobe was free from disease. Left hepatic
resection and colecistectomy were performed. When we removed
the giant mass during surgical procedure the patient had a hypo-
tensive crisis with severe bradycardia, but drug therapy saved
immediately the patient. The patient went back home in good
condition about 10 days later. Tc scan and blood exams didn't reveal
any abnormalities. The resected specimen was almost entirely
occupied by a 24 23 20 cm solid mass. Lesionwas 3 cm far from
resectionmargin. Neoplasia is organized in trabeculae, consisting of
cells with eosinophilic cytoplasm (Fig. 1). At immunohistochemical
examination neoplasia expressed synaptophysin, CD 56, Chro-
mogranin A, is negative for hepatocyte antigen. The Ki 67 is
expressed in about 5% of the neoplastic cells (Fig. 2). Immunohis-
tochemical data are summarized in Table 1. Final diagnosis
was neuroendocrine tumour NET G2 according to WHO 2010.
Differential diagnosis was made to hepatocellular carcinoma,
cholangiocellular carcinoma, hypervascularized metastasis, angio-
sarcoma, hemangiopericytoma, and a neuroendocrine tumour. At
36-month follow-up the patient shows no signs of liver recurrence
or appearance of a primary tumour or secondary extrahepatic
tumour. He is asymptomatic and fully functional. He performs only
a monthly administration of somatostatin.Fig. 1. Histochemical features of lesion: very vascularized neoplastic mass organized in trab
mitotic index. Haematoxylin & Eosin staining. Original magniﬁcation 4 (A); 10 (B); 203. Discussion
Carcinoid tumours actually known as well-differentiated
neuroendocrine tumours (NET) derive from neuroectodermal
cells dispersed throughout a lot of anatomical sites. The digestive
accounts about ﬁfty-four percent but they also in respiratory,
genital and head and neck district. In the United States the inci-
dence of carcinoid tumours is 6.25 cases per 100,000 per year [1,2].
Maggard et al. demonstrate that incidence rates for carcinoid tu-
mours have changed. The most common gastrointestinal site is not
the appendix (as is often quoted), but the small intestine, followed
in frequency by the rectum. The severity of pathology and survival
rates differ between individual anatomical sites [1]. The rate of
proliferation expresses by the number of mitoses per 10 high power
microscopic ﬁelds and the percentage of tumour cells immuno-
stained for Ki-67 antigen was introduced as the World Health Or-
ganization grading system of NET and correlates with prognosis.
Using that scores NET are classiﬁed into three types: well-
differentiated tumours of low grade malignancy with an indolent
development and a good prognosis; moderately differentiated or
intermediate grade neoplasms and poorly differentiated or high
grade epithelial neoplasms that carry a poor prognosis. NET has
typically slow growth and becomes clinically evident only at an
advanced stage [9e11]. Primary liver neuroendocrine tumours have
uncertain pathogenesis. They may originate from neuroendocrine
cells present in the intrahepatic bile ducts [7,8]. However, primary
hepatic NET is very rare and the ﬁrst case was documented by
Edmondson in 1958 [12]. In a range of presentation which goes
from 3 to 83 years old we can describe a middle age of presentation
of about 49e50 years old. Female are quite more affected by this
pathology than males (58% of cases). This tumour, initially occurs
without symptoms or with an unspeciﬁc abdominal pain. Othereculae, consisting of cells with eosinophilic cytoplasm, atypical nuclear aspect and low
(C); 40 (D).
Fig. 2. Immunohistochemical ﬁndings using ABC/HRP method. Immunostaining for PAN cytocheratine (A); original magniﬁcation 4. Immunostaining for CD 56 (B); original
magniﬁcation 10. Immunopositivity for Chromogranin (C); original magniﬁcation 10. Immunopositivity for synaptophysin (D); original magniﬁcation 20.
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rhoea. Few patients showed Cushing and ZollingereEllison syn-
dromes. The most frequently secreted hormones were gastrin (7/
69 ¼ 10.1%) and Chromogranin A. Most primary hepatic NETs are
non-secreting although few researches actually described the
secretion in the systemic circulation of several neuromediators like
serotonin, histamine, bradykinin, gastrin, vasoactive intestinal
peptide (VIP), insulin, glucagon, or prostaglandins [7,8]. Neo-
vascularization plays an important role in development of all he-
patic solid tumours. In hepatic neoplasms, neovascularization
status is correlated with disease progression and patient prognosis.
Endothelial progenitor cells (EPCs) have been proved to be themain
source of adult neovascularization [13]. It has been conﬁrmed that
neovascularization is vital to further multiplication, metastasis, and
recurrence in malignant tumours [14e16]. Differential diagnosis
between primary hepatic NET and secondary localization should be
established by number of masses and their size. A single large
centrally situated tumour is suggestive of a primary tumour
whereas neuroendocrine liver metastases present typically as
multiple diffuse liver masses. Diagnostics procedure have as
objective to detect the primary origin of the tumour and its









Cytocheratine 20 ecomputerized tomography, magnetic resonance, CT or MR enter-
oclysis, somatostatin scintigraphy, octreotide scan, PET scan,
gastroscopy, colonoscopy, endoscopic ultrasound of the pancreas,
bronchoscopy, video capsule endoscopy or balloon enteroscopy,
and operative exploration [17]. Hepatocellular carcinoma and
cholangiocarcinoma may present areas of neuroendocrine differ-
entiation [18,19]. Surgery should be the ﬁrst-line therapy for pa-
tients with liver neuroendocrine tumour. Norton demonstrates that
in primary and metastatic hepatic neuroendocrine tumour
aggressive surgical approach can be performed safely. It results in
excellent long-term survival and amelioration of symptoms [20].
However recurrences, mainly in the liver, remain high [21]. More
recently liver transplantation (LT) has been proposed in selected
patients that were not amenable to partial liver resection [22]. Liver
metastases from neuroendocrine tumour (NET) can be treated by
transarterial embolization (TAE) or transarterial chemo-
embolization (TACE) [23,24]. The interventional protocols for the
management of liver metastases from neuroendocrine tumours are
actually well described. For oligonodular liver metastatic deposits,
local resection and/or LT is recommended, while in multinodular
diseases with higher tumour load, TACE or TAE is recommended.
New strategies for advanced neuroendocrine tumours in the era of
targeted therapy are actually proposed. Several pathways and
angiogenesis as important targets for NETs new molecular thera-
pies [25]. In NETs, there is no hint of a remodelling of the Ca2þ
toolkit, that has been observed in other malignancies, including
renal cellular carcinoma [26e28], and prostate cancer [29],
myeloﬁbrosis [30], and has been put forward as alternative target
for selective molecular therapies [16]. In conclusion primary he-
patic carcinoid tumours are not frequent and their primary nature
can only be diagnosed after thorough investigations and long-term
follow-up. Aggressive surgical approach could be performed
because long-term survival and cure can be expected. In selected
A. Rocca et al. / International Journal of Surgery 12 (2014) S218eS221 S221patients not amenable to partial liver resection liver trans-
plantation can be considered. Some new therapeutic strategies are
actually proposed.
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